Casdin Capital, LLC Q3 2017 Filing
Filed November 14, 2017
Portfolio Value
$354.2B
Holdings
26
Report Date
Q3 2017
Filing Type
13F-HR
All Holdings (26 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | —LOXO ONCOLOGY INC | 360,000 | $33.2B | 9.36% | |
| 2 | —MYOKARDIA INC | 560,000 | $24.0B | 6.78% | |
| 3 | ALNYALNYLAM PHARMACEUTICALS INC | 200,000 | $23.5B | 6.63% | |
| 4 | GBYSANGAMO THERAPEUTICS INC | 1,400,000 | $21.0B | 5.93% | |
| 5 | 2L9BLUEPRINT MEDICINES CORP | 298,000 | $20.8B | 5.86% | |
| 6 | —BLUEBIRD BIO INC | 145,000 | $19.9B | 5.62% | |
| 7 | —FOUNDATION MEDICINE INC | 480,000 | $19.3B | 5.45% | |
| 8 | —KITE PHARMA INC | 106,000 | $19.1B | 5.38% | |
| 9 | —SPARK THERAPEUTICS INC | 209,474 | $18.7B | 5.27% | |
| 10 | AGIOAGIOS PHARMACEUTICALS INC | 255,000 | $17.0B | 4.81% | |
| 11 | VYGRVOYAGER THERAPEUTICS INC | 815,000 | $16.8B | 4.74% | |
| 12 | SG7SAGE THERAPEUTICS INC | 240,000 | $15.0B | 4.22% | |
| 13 | —GENMARK DIAGNOSTICS INC | 1,500,000 | $14.4B | 4.08% | |
| 14 | EVHEVOLENT HEALTH INC | 795,000 | $14.2B | 4.00% | |
| 15 | GBTUSDGLOBAL BLOOD THERAPEUTICS IN | 380,000 | $11.8B | 3.33% | |
| 16 | —AUDENTES THERAPEUTICS INC | 400,000 | $11.2B | 3.16% | |
| 17 | CLVSEURCLOVIS ONCOLOGY INC | 127,500 | $10.5B | 2.97% | |
| 18 | CDXSCODEXIS INC | 1,475,000 | $9.8B | 2.77% | |
| 19 | ILMNILLUMINA INC | 44,000 | $8.8B | 2.47% | |
| 20 | JNCEEURJOUNCE THERAPEUTICS INC | 399,825 | $6.2B | 1.76% | |
| 21 | —TESARO INC | 38,500 | $5.0B | 1.40% | |
| 22 | —SYROS PHARMACEUTICALS INC | 256,215 | $3.8B | 1.06% | |
| 23 | CTMXCYTOMX THERAPEUTICS INC | 177,500 | $3.2B | 0.91% | |
| 24 | EDITEDITAS MEDICINE INC | 133,333 | $3.2B | 0.90% | |
| 25 | FATEFATE THERAPEUTICS INC | 550,000 | $2.2B | 0.61% | |
| 26 | OVIDOVID THERAPEUTICS INC | 207,500 | $1.8B | 0.50% |